Reversal of fluoxetine-induced sexual dysfunction by switching to escitalopram.
Sexual dysfunction is a common complaint among patients taking selective serotonin reuptake-inhibiting (SSRI) antidepressants. Many options in managing this side effect have been described but none clearly is a first choice among clinicians. This paper describes the first published case of a patient having successful reversal of SSRI-induced sexual dysfunction by switching from an SSRI to escitalopram, the newest antidepressant and SSRI approved for use in the United States. Clinical implication is discussed.
Ashton
Adam Keller
AK
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects; D015283:Citalopram / Q000008:administration & dosage*; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy* / Q000523:psychology; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors